Overview
Hyperphosphatemia is a medical condition characterized by high levels of phosphates in the blood. It is commonly seen in patients with chronic kidney disease and is associated with an increased risk of cardiovascular disease and mortality. Hyperphosphatemia can be managed by restricting dietary intake of phosphorus and using medications that bind phosphates in the gastrointestinal tract, preventing their absorption into the bloodstream.
The hyperphosphatemia drugs market includes various types of drugs such as phosphate binders, vitamin D analogs, and calcimimetics. Phosphate binders are the most commonly used drugs for managing hyperphosphatemia. They work by binding with dietary phosphates in the gastrointestinal tract, preventing their absorption into the bloodstream. The most commonly used phosphate binders include calcium-based binders (such as calcium carbonate and calcium acetate), aluminum-based binders (such as aluminum hydroxide), and sevelamer-based binders.
Vitamin D analogs, such as calcitriol and paricalcitol, are used in combination with phosphate binders to manage hyperphosphatemia in patients with chronic kidney disease. They work by regulating calcium and phosphate metabolism in the body.
Calcimimetics, such as cinacalcet, are a newer class of drugs used for managing hyperphosphatemia in patients with chronic kidney disease. They work by decreasing the secretion of parathyroid hormone (PTH), which in turn reduces the absorption of phosphates from the gastrointestinal tract.
The hyperphosphatemia drugs market is driven by the increasing prevalence of chronic kidney disease and the associated risk of hyperphosphatemia. The market is also expected to grow due to the introduction of new and improved drugs, increased awareness among patients and healthcare professionals, and the availability of favorable reimbursement policies. However, the market growth may be limited by the high cost of these drugs and the potential for adverse effects associated with their long-term use.
Segment Overview
The hyperphosphatemia drugs market can be segmented based on drug class, distribution channel, and geography.
1) By drug class:
• Phosphate Binders
o Calcium-based binders
o Aluminum-based binders
o Sevelamer-based binders
o Lanthanum-based binders
o Iron-based binders
• Vitamin D Analogs
• Calcimimetics
2) By distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
3) By geography:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
The phosphate binder segment is expected to hold the largest market share due to its high usage in managing hyperphosphatemia. The hospital pharmacies segment is expected to dominate the distribution channel segment due to the requirement of administration of these drugs in a healthcare setting. Geographically, North America is expected to hold the largest market share due to the high prevalence of chronic kidney disease and the presence of key players in the region. However, the Asia Pacific region is expected to witness significant growth due to the increasing awareness of hyperphosphatemia and the increasing incidence of chronic kidney disease in the region.
Geography Overview
The hyperphosphatemia drugs market can be segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
1) North America:
North America is expected to hold the largest market share due to the high prevalence of chronic kidney disease, high awareness of hyperphosphatemia and its associated risks, and the presence of key players in the region. The US is expected to be the major contributor to the market growth in North America.
2) Europe:
Europe is expected to hold a significant market share due to the increasing incidence of chronic kidney disease and a growing geriatric population. The UK, Germany, France, and Italy are expected to be the major contributors to the market growth in Europe.
3) Asia Pacific:
The Asia Pacific region is expected to witness significant growth due to the increasing awareness of hyperphosphatemia and the increasing incidence of chronic kidney disease in the region. The growing geriatric population, increasing healthcare expenditure, and increasing adoption of western lifestyles are expected to drive market growth in this region. China, Japan, and India are expected to be the major contributors to the market growth in Asia Pacific.
4) Latin America:
Latin America is expected to witness moderate growth due to the growing prevalence of chronic kidney disease and increasing awareness of hyperphosphatemia. Brazil and Mexico are expected to be the major contributors to the market growth in Latin America.
5) Middle East & Africa:
The Middle East & Africa region is expected to witness moderate growth due to the growing prevalence of chronic kidney disease and increasing adoption of western lifestyles. Saudi Arabia, South Africa, and UAE are expected to be the major contributors to the market growth in the Middle East & Africa.
Overall, the hyperphosphatemia drugs market is expected to witness significant growth globally due to the increasing prevalence of chronic kidney disease and associated risks, the introduction of new and improved drugs, and the availability of favourable reimbursement policies.
COVID Impact
The COVID-19 pandemic has had a mixed impact on the hyperphosphatemia drugs market.
On one hand, the pandemic has led to a significant increase in the incidence of chronic kidney disease and associated risks, including hyperphosphatemia. This has driven the demand for hyperphosphatemia drugs. Additionally, the increased focus on healthcare infrastructure and the availability of favourable reimbursement policies have also supported market growth.
On the other hand, the pandemic has disrupted supply chains and manufacturing processes, leading to shortages of drugs in some regions. The pandemic has also led to a shift in focus towards the management of COVID-19, diverting resources away from other healthcare areas. This has led to delays in diagnosis and treatment of chronic kidney disease and hyperphosphatemia, which may have impacted market growth.
Furthermore, the pandemic has led to changes in healthcare delivery models, with a greater emphasis on telemedicine and home healthcare services. This has impacted the distribution channels for hyperphosphatemia drugs, with a shift towards online pharmacies and home delivery. This may have implications for the market in the long term, as patients become more accustomed to these modes of healthcare delivery.
In summary, the COVID-19 pandemic has had a mixed impact on the hyperphosphatemia drugs market, with both positive and negative effects. While the pandemic has driven demand for these drugs, disruptions in supply chains and changes in healthcare delivery models may have impacted market growth in the short and long term.
Competitive Analysis
The hyperphosphatemia drugs market is highly competitive and is characterized by the presence of several key players. Some of the major players operating in the market include:
1) Sanofi S.A.
2) Vifor Pharma Management Ltd.
3) Fresenius Medical Care AG & Co. KGaA
4) F. Hoffmann-La Roche AG
5) Keryx Biopharmaceuticals, Inc. (Akebia Therapeutics)
6) Shire Plc. (Takeda Pharmaceutical Company Limited)
7) AstraZeneca plc.
8) Pfizer Inc.
9) Amgen Inc.
10) GlaxoSmithKline plc.
These companies have been focusing on strategies such as mergers and acquisitions, collaborations, partnerships, and product launches to strengthen their market presence and expand their product portfolios.
For example, in December 2020, Vifor Pharma Management Ltd. announced the acquisition of the global rights to commercialize AKB-6548, a hypoxia-inducible factor prolyl hydroxylase inhibitor, from Akebia Therapeutics. The acquisition is expected to strengthen Vifor Pharma's position in the hyperphosphatemia drugs market.
Similarly, in September 2021, Amgen Inc. announced the launch of Parsabiv (etelcalcetide) in Japan for the treatment of secondary hyperparathyroidism (HPT) in chronic kidney disease (CKD) patients on hemodialysis. The launch is expected to strengthen Amgen's position in the hyperphosphatemia drugs market in Japan.
Overall, the hyperphosphatemia drugs market is expected to witness intense competition in the coming years as key players continue to focus on expanding their product portfolios and strengthening their market presence through strategic initiatives.